Condition

TNBC - Triple-Negative Breast Cancer clinical trials and research

• 38Clinical trials
• 14Countries

Newest TNBC - Triple-Negative Breast Cancer clinical trials

All recruiting trials (38)

• Imaging Test for Metastatic Urothelial and Breast C cancers and NSCLC

  This imaging study tests how well the imaging agent works in people with metastatic urothelial cancer, various breast cancers, or NSCLC.

  Recruiting at 4 sites Early Phase 1 RayzeBio, Inc. · St Leonards, New South Wales and 5 other locations · NCT07671092

• Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases

  This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07638852

• First-line therapy for advanced TNBC with QL1706, plus anlotinib and nab-paclitaxel

  This study tests whether a combination of QL1706 with anlotinib and nab-paclitaxel can help people with newly diagnosed, advanced triple-negative breast cancer.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu · NCT07601178

• Patient-reported outcomes of sacituzumab govitecan versus physician‑choice chemotherapy in Chinese metastatic HER2‑negative breast cancer

  This project will test whether sacituzumab govitecan or physician‑choice chemotherapy leads to better patient‑reported quality of life and symptoms for Chinese adults aged 18–75 with metastatic HER2‑negative breast cancer who progressed after first‑line treatment.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07551050

• Short-course SBRT plus toripalimab and chemotherapy for chemo-resistant triple-negative breast cancer

  This trial will try a short, high-precision course of breast radiation followed by toripalimab with paclitaxel and carboplatin for people whose triple-negative breast cancer did not shrink after initial chemotherapy to see if it can eliminate invasive cancer at surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07457359

• Neoadjuvant chemotherapy with sintilimab and bevacizumab for triple-negative breast cancer

  This trial will try adding the immunotherapy drug sintilimab and the blood‑vessel blocker bevacizumab to pre-surgery chemotherapy for women with stage II–III triple‑negative breast cancer to see if more tumors disappear completely before surgery.

  Recruiting at 2 sites Phase 2 First Affiliated Hospital of Zhejiang University · Hefei and 1 other locations · NCT07351487

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• MRI-guided early surgery and reduced chemotherapy for stage II–III triple-negative breast cancer

  This trial will try using MRI to decide whether adults with stage II–III triple-negative breast cancer who are receiving a pembrolizumab-containing neoadjuvant regimen can have earlier surgery and less chemotherapy.

  Recruiting at 2 sites Phase 2 Tel-Aviv Sourasky Medical Center · Tel Aviv and 1 other locations · NCT07327021

• Fluzoparib maintenance in platinum-sensitive advanced triple-negative breast cancer

  This study tests whether continuing Fluzoparib as maintenance therapy helps people with BRCA mutation–associated or non–BRCA-mutant platinum-sensitive advanced TNBC stay disease-free longer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07321015

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors

  This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.

  Recruiting at 5 sites Phase 1/2 Radiopharm Theranostics, Ltd · Dothan, Alabama and 4 other locations · NCT07189871

• QL1706 plus short-cycle anthracycline or taxane chemotherapy for early-stage triple-negative breast cancer

  This trial will test whether adding QL1706, a dual PD-1/CTLA-4 antibody, to short-cycle anthracycline- or taxane-based chemotherapy helps patients with newly diagnosed early-stage triple-negative breast cancer.

  Recruiting Phase 1 Xijing Hospital · Xi'an, Shaanxi · NCT07178171

• SC-101 in NECTIN4-amplified cancers

  This study tests SC-101 as a stand-alone treatment in adults with NECTIN4 amplification and advanced or metastatic TNBC, HR+ breast cancer, or other solid tumors to see if it can shrink tumors and be safe.

  Recruiting Phase 2 Tianjin ConjuStar Biologics Co., Ltd. · Shanghai, Shanghai Municipality · NCT07080619

• Trop‑2–targeted PET imaging for advanced triple‑negative breast cancer

  This project will test whether a Trop‑2–targeted PET scan (89Zr‑DFO‑hSR7) can find Trop‑2–positive tumors and track response to sacituzumab govitecan in people with advanced triple‑negative breast cancer.

  Recruiting Peking University Cancer Hospital & Institute · Beijing · NCT07046455

• Ivonescimab with carboplatin and docetaxel for early triple-negative breast cancer

  This trial will test whether adding ivonescimab to neoadjuvant carboplatin and docetaxel helps people with early-stage triple-negative breast cancer.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Los Angeles, California and 3 other locations · NCT07017673

• QL1706 combined with chemotherapy for treating advanced triple negative breast cancer

  This study is testing a new treatment combining QL1706 with chemotherapy to see if it helps women with advanced triple negative breast cancer feel better compared to standard options.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06786026

• Combining chemotherapy with Toripalimab for treating triple negative breast cancer

  This study is testing if combining chemotherapy with Toripalimab can help women with triple negative breast cancer respond better to treatment before surgery.

  Recruiting at 8 sites Phase 2 First Affiliated Hospital of Zhejiang University · Nanchang, Jiangxi and 12 other locations · NCT06682195

• Testing TUB-030 for advanced solid tumors

  This study is testing a new drug called TUB-030 to see if it can safely help adults with advanced solid tumors, especially those with head and neck cancer or non-small cell lung cancer.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · New Haven, Connecticut and 19 other locations · NCT06657222

• Treatment for locally advanced triple negative breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it can safely help people with locally advanced triple negative breast cancer feel better and improve their chances of survival.

  Recruiting Early Phase 1 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06637306

• SBRT plus PD-1 immunotherapy and chemotherapy for early-stage triple-negative breast cancer

  This tests whether adding stereotactic body radiotherapy (SBRT) to a PD-1 drug and chemotherapy helps people with early-stage triple-negative breast cancer get better responses to treatment.

  Recruiting Phase 3 West China Hospital · Sichuan, Chengdu · NCT06627712

• Milaberon for treating advanced solid tumors

  This study is testing if a higher dose of mirabegron can help people with advanced solid tumors feel better while keeping an eye on any side effects.

  Recruiting Phase 2 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT06534762

• Combination of LM-108 and PD-1 treatment for advanced triple-negative breast cancer

  This study is testing a new combination of treatments for people with advanced triple-negative breast cancer to see if it helps them feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06387628

• Treatment for early triple-negative breast cancer using INT230-6 and immuno-chemotherapy

  This study is testing a new treatment called INT230-6, combined with chemotherapy, to see if it can help people with early-stage triple-negative breast cancer have better outcomes before surgery.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Lyon and 9 other locations · NCT06358573

• Using 177Lu-anti-PD-L1 for treating metastatic solid tumors

  This study is testing a new treatment called 177Lu-RAD204 to see if it can safely help people with advanced solid tumors like lung cancer and melanoma.

  Recruiting at 4 sites Early Phase 1 Radiopharm Theranostics, Ltd · Gosford, New South Wales and 5 other locations · NCT06305962

• Using ctDNA to monitor treatment response in triple-negative breast cancer

  This study is testing if checking for cancer DNA in the blood can help doctors see how well treatment is working for people with triple-negative breast cancer after they receive chemotherapy.

  Recruiting at 14 sites Personalis Inc. · Tucson, Arizona and 13 other locations · NCT06230185

• Using advanced mammography techniques to assess breast cancer treatment response

  This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT06220214

• Assessing PSMA in Patients with Progressive Triple-Negative Breast Cancer

  This study is testing if a special imaging technique can help find a targeted treatment for patients with advanced triple-negative breast cancer.

  Recruiting Phase 2 Jules Bordet Institute · Brussels · NCT06059469

• Combining Camrelizumab and Chemotherapy for Triple-Negative Breast Cancer Treatment

  This study is testing if adding a new drug called camrelizumab, with or without famitinib, to standard chemotherapy can improve treatment for people with triple-negative breast cancer before surgery.

  Recruiting at 2 sites Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT05999149

• Investigating CRP Levels in Triple-Negative Breast Cancer During Immunotherapy

  This study is testing if changes in a blood marker called CRP can help predict how well immunotherapy works for people with triple-negative breast cancer.

  Recruiting University Hospital Tuebingen · Tübingen · NCT05914961

• Treatment of advanced solid tumors with AVZO-021

  This study is testing a new oral medication called AVZO-021 to see if it can safely help people with advanced solid tumors, especially certain types of breast cancer and other cancers with specific genetic changes.

  Recruiting at 13 sites Phase 1/2 Avenzo Therapeutics, Inc. · New Haven, Connecticut and 12 other locations · NCT05867251

• Combining PD-1 therapy with chemotherapy for triple-negative breast cancer

  This study is testing if a new combination of a PD-1 therapy and chemotherapy can help people with early-stage triple-negative breast cancer do better than standard treatments.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05862064

• Testing BAL0891 for advanced solid tumors and acute myeloid leukemia

  This study is testing a new treatment called BAL0891 to see if it can safely help people with advanced solid tumors or acute myeloid leukemia.

  Recruiting at 15 sites Phase 1 SillaJen, Inc. · New Haven, Connecticut and 16 other locations · NCT05768932

• Combining alpelisib with chemotherapy for HER2 negative metaplastic breast cancer

  This study is testing whether combining a new drug called alpelisib with chemotherapy can help people with a rare and tough type of breast cancer feel better and improve their treatment results.

  Recruiting at 3 sites Phase 2 The Methodist Hospital Research Institute · Bethesda, Maryland and 2 other locations · NCT05660083

• Using PET/CT imaging to evaluate estrogen receptors in breast cancer

  This study is testing a special type of imaging to see how well it can measure estrogen receptors in patients with breast cancer to help improve their treatment options.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT05541367

• Boosting immunotherapy response in high-risk triple-negative breast cancer with CSF-1R blockade and radiation

  This will try pembrolizumab with axatilimab and radiation before surgery to see if it increases complete tumor disappearance in adults with high-risk triple-negative breast cancer.

  Recruiting Phase 2 Cedars-Sinai Medical Center · Los Angeles, California · NCT05491226

• Examining the immune environment in different types of breast cancer

  This study looks at tissue samples from women with different types of breast cancer to see how the immune environment affects treatment responses.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT05396612

• Combining radiation therapy with pembrolizumab and olaparib for certain breast cancers

  This study tests if adding pembrolizumab, with or without olaparib, to standard radiation therapy can help women with advanced breast cancer feel better compared to just radiation therapy alone.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04683679

• Personalized treatment for breast cancer using new drug agents

  This study is testing new drug combinations with standard chemotherapy to see which treatments work best for different types of breast cancer based on the specific characteristics of each patient's tumor.

  Recruiting at 32 sites Phase 2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 41 other locations · NCT01042379

Related topics

Quick answers

How many TNBC - Triple-Negative Breast Cancer clinical trials are recruiting right now?

38, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in China (17 trials), United States (15 trials), Australia (3 trials), France (2 trials), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 18, Early Phase 1: 4, Phase 1/2: 3, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →